APA-Zitierstil (7. Ausg.)

Hindié, E. (2023). Dalpiciclib in advanced breast cancer: Introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy. The lancet oncology, 24(9), e356. https://doi.org/10.1016/S1470-2045(23)00360-1

Chicago-Zitierstil (17. Ausg.)

Hindié, Elif. "Dalpiciclib in Advanced Breast Cancer: Introducing CDK4/6 Inhibitors as a First-line Treatment Might Not Be the Best Strategy." The Lancet Oncology 24, no. 9 (2023): e356. https://doi.org/10.1016/S1470-2045(23)00360-1.

MLA-Zitierstil (9. Ausg.)

Hindié, Elif. "Dalpiciclib in Advanced Breast Cancer: Introducing CDK4/6 Inhibitors as a First-line Treatment Might Not Be the Best Strategy." The Lancet Oncology, vol. 24, no. 9, 2023, p. e356, https://doi.org/10.1016/S1470-2045(23)00360-1.